Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
28 Nov 2023
Historique:
received: 23 05 2023
revised: 15 08 2023
accepted: 14 11 2023
medline: 30 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: ppublish

Résumé

In the general population, physical activity has been associated with a lower risk of several cancers; however, the evidence for ovarian cancer is not clear. It is suggested that early-life physical activity may differentially impact risk. Whether this is true among women at high risk due to a pathogenic variant (mutation) in the BRCA1 or BRCA2 genes has not been evaluated. Thus, we performed a matched case-control study to evaluate the association between adolescent and early-adulthood physical activity and ovarian cancer. BRCA mutation carriers who completed a research questionnaire on various exposures and incident disease and with data available on physical activity were eligible for inclusion. Self-reported activity at ages 12-13, 14-17, 18-22, 23-29, and 30-34 was used to calculate the average metabolic equivalent of task (MET)-hours/week for moderate, vigorous, and total physical activity during adolescence (ages 12-17) and early-adulthood (ages 18-34). Conditional logistic regression was used to estimate the OR and 95% confidence intervals (CI) of invasive ovarian cancer associated with physical activity. This study included 215 matched pairs (mean age = 57.3). There was no association between total physical activity during adolescence (ORhigh vs. low = 0.91; 95% CI: 0.61-1.36; Ptrend = 0.85), early-adulthood (ORhigh vs. low = 0.78; 95% CI: 0.51-1.20; Ptrend = 0.38) and overall (ORhigh vs. low = 0.81; 95% CI: 0.54-1.23; Ptrend = 0.56) and ovarian cancer. Findings were similar for moderate (Ptrend ≥ 0.25) and vigorous (Ptrend ≥ 0.57) activity. These findings do not provide evidence for an association between early-life physical activity and BRCA-ovarian cancer; however, physical activity should continue to be encouraged to promote overall health. In this matched case-control study, we observed no association between physical activity during adolescence or early-adulthood and subsequent risk of ovarian cancer. These findings do not provide evidence for an association between early-life physical activity and BRCA-ovarian cancer; however, being active remains important to promote overall health and well-being.

Identifiants

pubmed: 38019076
pii: 731420
doi: 10.1158/2767-9764.CRC-23-0223
pmc: PMC10683556
doi:

Substances chimiques

BRCA1 protein, human 0
BRCA1 Protein 0
BRCA2 protein, human 0
BRCA2 Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2420-2429

Subventions

Organisme : CCS | Canadian Cancer Society Research Institute (CCSRI)
ID : 703058
Organisme : Peter Gilgan Foundation (The Peter Gilgan Foundation)
Organisme : CIHR Canada Graduate Scholarships Doctoral Award
Organisme : Tier II Canada Research Chair
Organisme : Sondra J and Stephen R Hardis Endowed Chair of Cancer Genomic Medicine
Organisme : Tier I Canada Research Chair

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Références

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2321-30
pubmed: 18006921
Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
Obstet Gynecol. 2000 Oct;96(4):609-14
pubmed: 11004368
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Br J Cancer. 1987 Jun;55(6):681-5
pubmed: 3620313
Carcinogenesis. 2022 Apr 25;43(3):231-242
pubmed: 34958358
Int J Cancer. 2006 Jun 15;118(12):3153-60
pubmed: 16425259
Int J Cancer. 2016 Feb 15;138(4):843-52
pubmed: 26335147
Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2038-2043
pubmed: 34426412
Cancer Causes Control. 2010 Dec;21(12):2183-94
pubmed: 20827504
Lancet Oncol. 2013 Nov;14(12):1226-32
pubmed: 24140203
Gynecol Oncol. 2020 Dec;159(3):820-826
pubmed: 33010967
Am J Prev Med. 2022 Nov;63(5):837-845
pubmed: 35738959
Int J Epidemiol. 1994 Oct;23(5):991-9
pubmed: 7860180
Int J Cancer. 2020 Apr 1;146(7):1800-1809
pubmed: 31199510
Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2000-8
pubmed: 23966580
Lancet. 2021 Jun 5;397(10290):2182-2193
pubmed: 33991479
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20
pubmed: 28040716
Int J Cancer. 2001 Feb 1;91(3):407-11
pubmed: 11169967
J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86
pubmed: 9839517
CA Cancer J Clin. 2022 May;72(3):230-262
pubmed: 35294043
JNCI Cancer Spectr. 2019 Oct 17;4(1):pkz080
pubmed: 32337494
Int J Cancer. 2002 May 20;99(3):431-6
pubmed: 11992414
Cancer Causes Control. 2010 Apr;21(4):485-91
pubmed: 19953315
Eur J Epidemiol. 2004;19(11):1011-9
pubmed: 15648594
Eur J Cancer Prev. 2009 Aug;18(4):322-30
pubmed: 19390450
Med Sci Sports Exerc. 2019 Jun;51(6):1252-1261
pubmed: 31095082
Breast Cancer Res. 2015 Nov 05;17(1):139
pubmed: 26541144
Int J Cancer. 2021 Dec 15;149(12):2045-2051
pubmed: 34398976
Hered Cancer Clin Pract. 2020 Mar 07;18:5
pubmed: 32165993
Gynecol Oncol. 2018 Jul;150(1):85-91
pubmed: 29793803
Gynecol Oncol. 2015 Jun;137(3):559-73
pubmed: 25797080

Auteurs

Emma Guyonnet (E)

Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.

Shana J Kim (SJ)

Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Yue Yin Xia (YY)

Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

Vasily Giannakeas (V)

Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
ICES, Toronto, Ontario, Canada.

Jan Lubinski (J)

International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.

Susan Randall Armel (S)

Bhalwani Familial Cancer Clinic, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Department of Medical Genetics, University of Toronto, Toronto, Ontario, Canada.

Andrea Eisen (A)

Toronto-Sunnybrook Regional Cancer Center, Toronto, Canada.

Louise Bordeleau (L)

Department of Oncology, Juravinski Cancer Centre, Hamilton, Canada.

Charis Eng (C)

Genomic Medicine Institute, Center for Personalised Genetic Healthcare, Cleveland Clinic, Cleveland, Ohio.

Olufunmilayo I Olopade (OI)

Department of Medicine and Human Genetics, University of Chicago, Chicago, Illinois.

Nadine Tung (N)

Beth Israel Deaconess Medical Center, Boston, Massachusetts.

William D Foulkes (WD)

Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montréal, Quebec, Canada.

Fergus J Couch (FJ)

Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Amber M Aeilts (AM)

Division of Human Genetics, Ohio State University Medical Center, Comprehensive Cancer Center, Columbus, Ohio.

Steven A Narod (SA)

Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Joanne Kotsopoulos (J)

Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH